Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02708628
Other study ID # AGZ-EAC-A-H-1
Secondary ID
Status Completed
Phase N/A
First received February 29, 2016
Last updated October 2, 2016
Start date December 2015
Est. completion date October 2016

Study information

Verified date March 2016
Source Suleymaniye Birth And Women's Health Education And Research Hospital
Contact n/a
Is FDA regulated No
Health authority Turkey: Ministry of Health
Study type Interventional

Clinical Trial Summary

To investigate the efficacy of prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin after surgical removal of the primary cesarean scar in the second cesarean section.


Description:

120 patients who are admitted for the second cesarean delivery, not taking prophylactic medication after the first cesarean section, whose scar development and measurements are taken will be included in the study. First caesarean section scars will be removed surgically for all patients. 60 out of 120 patients (treatment group) will use prophylactic topical scar gel 2 times in a day, and remaining 60 patients (control group )won't use. The efficacy of the drug will be evaluated by taking strict measurements of the incision and POSAS (The Patient and Observer Scar Assessment Scale) and Vancouver Scales at 6.12 and 24 weeks.

Steps;

1. Observation of the primary cesarean scar by taking scar measurements and using Vancouver and POSAS scales.

2. Surgical removal of the primary cesarean scar in the second cesarean section.

3. 24 weeks topical application of gel containing extract of allium cepae, allantoin and heparin(only treatment group).

4. Observation of the skin incision at 6,12 and 24 weeks by taking scar measurements with using Vancouver and POSAS scales.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date October 2016
Est. primary completion date April 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Patients who are admitted for the second cesarean delivery

- Not to use topical scar gel after the first c-section

Exclusion Criteria:

- chronic illness, immunosuppressive therapy or smoking

- development of wound infection during the second c- section

- allergies and hypersensitivities to components of the gel

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
extract of allium cepae, allantoin and heparin
prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
Procedure:
Scar excision
Scar excision in second c-section

Locations

Country Name City State
Turkey Suleymaniye Birth And Women's Health Education And Research Hospital. Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Suleymaniye Birth And Women's Health Education And Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary POSAS observer score change will be assessed by POSAS observer scale (The Patient and Observer Scar Assessment Scale v2.0) just prior to second c-section and at 6,12 and 24 weeks following the c-section. just prior to second c-section and at 6,12,24 weeks No
Primary POSAS patient score change will be assessed by POSAS patient scale (The Patient and Observer Scar Assessment Scale v2.0) just prior to second c-section and at 6,12 and 24 weeks following the c-section. just prior to second c-section and at 6,12,24 weeks No
Primary Vancouver scar score change will be assessed by Vancouver scar scale just prior to second c-section and at 6,12 and 24 weeks following the c-section. just prior to second c-section and at 6,12,24 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02645773 - Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring N/A
Completed NCT02672956 - Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results N/A
Completed NCT00629811 - Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women Phase 2
Completed NCT00847795 - Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects. Phase 1/Phase 2
Completed NCT00977951 - Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects Phase 1/Phase 2
Not yet recruiting NCT03213548 - Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty N/A
Recruiting NCT05377723 - Abdominal Scar Improvement in Microsurgical Breast Reconstruction N/A
Active, not recruiting NCT01976260 - A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars N/A
Terminated NCT00432328 - Juvista (Avotermin) in Breast Reduction Surgery Scars Phase 2
Completed NCT00984503 - Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites Phase 2
Completed NCT00594581 - Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males Phase 2
Recruiting NCT04420442 - Scar Resection and Reconstruction With Integra and Split Skin Grafts in Patients With Non-Suicidal Self-Inflicted Scars N/A
Completed NCT02772289 - Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars Phase 2
Completed NCT00430326 - Juvista (Avotermin) in Scars Following Varicose Vein Removal Phase 2
Completed NCT00847925 - Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects Phase 1/Phase 2
Recruiting NCT05787171 - Three Sutures With Different Absorption Rates for Lower Abdominal Incision N/A
Completed NCT02985151 - Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy N/A
Completed NCT02340325 - FS2 Safety and Tolerability Study in Healthy Volunteers Phase 1
Active, not recruiting NCT00432211 - Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery. Phase 2
Completed NCT00978302 - Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista) Phase 1